1:21 PM
 | 
Feb 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ASN100: Ph II started

Arsanis began a double-blind, placebo-controlled, international Phase II trial to evaluate a single dose of IV ASN100 in about 350 high-risk, mechanically ventilated patients. ASN100 was discovered under a...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >